Clinical trial · Observational
Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population
A Multi-center Randomized Control Study of Bronchoscopy in Early Lung Cancer Screening of High Risk Population
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): We have recruited some patients, but we haven't found any significant result by bronchoscopy in the high risk population.
Summary
Brief summary (as posted)
The purpose of this study is to determine the diagnostic yield of early lung cancer in high risk population, who smokes or has other risk factors, by different bronchoscopy,. Furthermore, another purpose is to determine whether the different bronchoscopy are significant different in diagnosing early lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fluorescence Bronchoscopy/Narrow Band Bronchoscopy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Fluorescence/Narrow Band Bronchoscopy
- description
- All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
- interventionNames
- Procedure: Fluorescence Bronchoscopy/Narrow Band Bronchoscopy
- label
- Routine Bronchoscopy
- description
- All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.
Primary outcomes (1)
- measure
- Diagnostic yield of Lung Cancer
- timeFrame
- 1 week
Secondary outcomes (1)
- measure
- Number of Participants with Serious Adverse Events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is over 40 years in age and is a heavy cigarette smoker.(smoking index is over 400) * Patient has been coughing irritably for 2-3 weeks with a failed treatment and without obvious causes. * The nature of cough changes in a patient who has chronic respiratory disease. * Patient has blood-stained sputum persistently or repeatedly without obvious causes. Patient will be included if accorded with any item of above. Exclusion Criteria: * Patient has dysrhythmia or cardiovascular disease that poses a risk during exercise. * Patient has uncontrollable hypertension (SBP \> 180mmHg). * Patient has severe organ dysfunction (shock, severe hepatic and renal dysfunction, massive hemorrhage of upper gastrointestine, diffuse intravascular coagulation(DIC) and massive hemoptysis,etc). * Patient has blood coagulation disorders (PT\>2 times the upper limit of normal(ULN) or Platelet(PLT)\<50000/ul). * Patient has severe dyspnea. * Patient is allergic to local anesthetic. * Patient is unable to provide informed consent. * Patient is not an appropriate candidate for or is unable to tolerate flexible bronchoscopy procedures. * Patient has any disease or condition that interferes with completion of initial or follow-up assessments of the effectiveness endpoints. * Patient has demonstrated unwillingness or inability to complete screening or baseline data collection procedures. * Patient participated in a study of an investigational drug or device within the past 30 days prior to participation in this study, or is currently participating in another clinical study. * Patient has pulmonary lesions suspected to be cancer from CT images. * Female patient of childbearing potential has a positive result from a pregnancy test.
References
Publications (5)
- BACKGROUNDMoghissi K, Dixon K, Stringer MR. Current indications and future perspective of fluorescence bronchoscopy: a review study. Photodiagnosis Photodyn Ther. 2008 Dec;5(4):238-46. doi: 10.1016/j.pdpdt.2009.01.008. Epub 2009 Feb 23. PMID 19356663
- BACKGROUNDAli AH, Takizawa H, Kondo K, Nakagawa Y, Toba H, Khasag N, Kenzaki K, Sakiyama S, Mohammadien HA, Mokhtar EA, Tangoku A. Follow-up using fluorescence bronchoscopy for the patients with photodynamic therapy treated early lung cancer. J Med Invest. 2011 Feb;58(1-2):46-55. doi: 10.2152/jmi.58.46. PMID 21372486
- BACKGROUNDEdell E, Lam S, Pass H, Miller YE, Sutedja T, Kennedy T, Loewen G, Keith RL, Gazdar A. Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial. J Thorac Oncol. 2009 Jan;4(1):49-54. doi: 10.1097/JTO.0b013e3181914506. PMID 19096306
- BACKGROUNDVenmans BJ, Van Boxem TJ, Smit EF, Postmus PE, Sutedja TG. Results of two years expenience with fluorescence bronchoscopy in detection of preinvasive bronchial neoplasia. Diagn Ther Endosc. 1999;5(2):77-84. doi: 10.1155/DTE.5.77. PMID 18493485
- BACKGROUNDGabrecht T, Lovisa B, van den Bergh H, Wagnieres G. Autofluorescence bronchoscopy: quantification of inter-patient variations of fluorescence intensity. Lasers Med Sci. 2009 Jan;24(1):45-51. doi: 10.1007/s10103-007-0518-y. Epub 2007 Nov 30. PMID 18060444